Clinical Predictors of Good/Poor Response to Growth Hormone Treatment in Children with Idiopathic Short Stature.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Children with idiopathic short stature (ISS) are known to have varying responses to growth hormone (GH) treatment (GHT).

Who Took Part

By PubMed's age tags, the people studied were young children and children, both men and women.

Patients were grouped according to their response to GHT; good, middle, and poor responders had a change in HSDS of >1.0, 0.4-1.0, and <0.4, respectively.

How the Study Was Run

In design terms this was a randomized study.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

The researchers conducted a post hoc analysis to identify clinical characteristics predictive of good and poor response during year 1 of GHT.

Data from the NordiNet® IOS (NCT00960128) and the ANSWER Program (NCT01009905) were used.

Logistic regression modelling was performed to identify clinical characteristics predictive of response to GHT.

What Was Measured

PubMed files the paper under topics including Human Growth Hormone, Growth Disorders and Body Height.

The authors tagged it with the keywords Growth hormone treatment, Idiopathic short stature, Paediatric growth hormone disorder and Predictors of response.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Hormone research in paediatrics), a journal based in Switzerland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.